These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 15277696

  • 1. Cellular immunotherapy with dendritic cells in cancer: current status.
    Nencioni A, Brossart P.
    Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy with dendritic cells for cancer.
    Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A.
    Adv Drug Deliv Rev; 2008 Jan 14; 60(2):173-83. PubMed ID: 17977615
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
    Murakami T, Tokunaga N, Waku T, Gomi S, Kagawa S, Tanaka N, Fujiwara T.
    Clin Cancer Res; 2004 Jun 01; 10(11):3871-80. PubMed ID: 15173096
    [Abstract] [Full Text] [Related]

  • 4. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.
    Tyagi RK, Mangal S, Garg N, Sharma PK.
    Expert Rev Anticancer Ther; 2009 Jan 01; 9(1):97-114. PubMed ID: 19105710
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cells in cancer immunotherapy.
    Gunzer M, Grabbe S.
    Crit Rev Immunol; 2001 Jan 01; 21(1-3):133-45. PubMed ID: 11642600
    [Abstract] [Full Text] [Related]

  • 6. Development of vaccines against self-antigens: the p53 paradigm.
    Chada S, Mhashilkar A, Roth JA, Gabrilovich D.
    Curr Opin Drug Discov Devel; 2003 Mar 01; 6(2):169-73. PubMed ID: 12669451
    [Abstract] [Full Text] [Related]

  • 7. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials.
    Mossoba ME, Medin JA.
    Expert Rev Vaccines; 2006 Oct 01; 5(5):717-32. PubMed ID: 17181444
    [Abstract] [Full Text] [Related]

  • 8. Dendritic cells as vectors for immunotherapy of cancer.
    Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK.
    Semin Cancer Biol; 2003 Dec 01; 13(6):439-47. PubMed ID: 15001163
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines.
    Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT.
    Stem Cells; 1997 Dec 01; 15(2):94-103. PubMed ID: 9090785
    [Abstract] [Full Text] [Related]

  • 10. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K, Teramoto K, Ozaki Y, Sawai S, Tezuka N, Ishida H, Kajino K, Fujino S, Yamauchi A, Taguchi O, Kannagi R, Yokomise H, Ogasawara K.
    Oncol Rep; 2007 Apr 01; 17(4):895-902. PubMed ID: 17342333
    [Abstract] [Full Text] [Related]

  • 11. RNA pulsed dendritic cells: an approach for cancer immunotherapy.
    Garg NK, Dwivedi P, Prabha P, Tyagi RK.
    Vaccine; 2013 Feb 06; 31(8):1141-56. PubMed ID: 23306369
    [Abstract] [Full Text] [Related]

  • 12. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H, Shurin MR, Han B.
    Expert Rev Vaccines; 2007 Jun 06; 6(3):333-45. PubMed ID: 17542749
    [Abstract] [Full Text] [Related]

  • 13. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M, Kokhaei P.
    Cell Immunol; 2009 Jun 06; 257(1-2):23-31. PubMed ID: 19306994
    [Abstract] [Full Text] [Related]

  • 14. The use of dendritic cells for cancer vaccination.
    Esche C, Shurin MR, Lotze MT.
    Curr Opin Mol Ther; 1999 Feb 06; 1(1):72-81. PubMed ID: 11249687
    [Abstract] [Full Text] [Related]

  • 15. Taming cancer by inducing immunity via dendritic cells.
    Palucka AK, Ueno H, Fay JW, Banchereau J.
    Immunol Rev; 2007 Dec 06; 220():129-50. PubMed ID: 17979844
    [Abstract] [Full Text] [Related]

  • 16. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J.
    J Immunother; 2006 Dec 06; 29(5):499-511. PubMed ID: 16971806
    [Abstract] [Full Text] [Related]

  • 17. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R.
    Cancer J; 2001 Dec 06; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [Abstract] [Full Text] [Related]

  • 18. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT.
    Cancer Metastasis Rev; 2006 Jun 06; 25(2):233-42. PubMed ID: 16770535
    [Abstract] [Full Text] [Related]

  • 19. Dendritic cell immunotherapy: mapping the way.
    Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ.
    Nat Med; 2004 May 06; 10(5):475-80. PubMed ID: 15122249
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 May 06; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.